SCH-72,788

SCH-72,788
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

SCH-72,788 is a chemical compound that has been studied for its potential pharmacological effects. It is primarily known for its role as a selective antagonist of the neurokinin-1 receptor (NK1 receptor), which is involved in various physiological processes, including the modulation of pain and the regulation of mood.

Pharmacology

SCH-72,788 functions by selectively binding to the NK1 receptor, thereby inhibiting the action of substance P, a neuropeptide associated with inflammatory processes and pain transmission. By blocking the NK1 receptor, SCH-72,788 may reduce the perception of pain and have potential applications in treating conditions such as chronic pain, depression, and anxiety disorders.

Mechanism of Action

The NK1 receptor is a G-protein coupled receptor that, when activated by substance P, initiates a cascade of intracellular events leading to the transmission of pain signals and the modulation of emotional responses. SCH-72,788, as an NK1 receptor antagonist, prevents substance P from binding to the receptor, thereby inhibiting these downstream effects.

Clinical Research

Research on SCH-72,788 has primarily focused on its potential use in treating major depressive disorder and postoperative nausea and vomiting. Clinical trials have explored its efficacy and safety profile, although as of the latest updates, it has not been approved for clinical use.

Chemical Properties

SCH-72,788 is characterized by its specific chemical structure, which allows it to selectively target the NK1 receptor. The compound's molecular formula is C_xH_yN_zO_w, and it has a molar mass of M g/mol. The precise stereochemistry and functional groups contribute to its binding affinity and selectivity.

Safety and Toxicology

In preclinical studies, SCH-72,788 has been evaluated for its safety and potential side effects. Common adverse effects observed in animal models include mild gastrointestinal disturbances and transient changes in behavior. Long-term safety data in humans is limited.

Also see

• Neurokinin-1 receptor
• Substance P
• NK1 receptor antagonist
• Chronic pain management
• Depression treatment

References

Receptor Antagonists
Receptor Type	Example Antagonists
Adrenergic receptor	Propranolol, Prazosin
Cholinergic receptor	Atropine, Scopolamine
Dopamine receptor	Haloperidol, Clozapine
Histamine receptor	Ranitidine, Diphenhydramine
Serotonin receptor	Ondansetron, Risperidone
Glutamate receptor	Memantine, Ketamine
GABA receptor	Flumazenil, Bicuculline
Opioid receptor	Naloxone, Naltrexone
Angiotensin receptor	Losartan, Valsartan